Nasdaq
$0.9959▼ 0.39%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.1MShares out 9.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 6d agoPre-market26.10.19 21:55ARSOther#●●●#●●●
LISATA THERAPEUTICS, INC.
Lisata Therapeutics, Inc. has filed its Annual Report to Security Holders (ARS) for the fiscal year ended December 31, 2025. This filing provides shareholders with a comprehensive overview of the company's financial condition and business operations for the reported period.…more
$0.9959-0.39%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 6d agoPre-market26.10.19 19:38DEF 14AOther
LISATA THERAPEUTICS, INC.
Lisata Therapeutics has completed the acquisition of Marea Therapeutics and issued Series C preferred stock through a $225 million private placement. The upcoming annual meeting will seek stockholder approval for the conversion of these shares, a reverse stock split at a ratio between 1-for-5 and 1-for-15, and new equity incentive plans.…more
$0.9959-0.39%vs prev closeView filingShare - 10.16Overnight26.10.16 09:443Ownership
LISATA THERAPEUTICS, INC.
Jeff Farrow, an officer of Lisata Therapeutics, Inc., has executed a Power of Attorney to facilitate the filing of SEC documents. This authorization grants the company's management and legal counsel the authority to prepare and file Forms 3, 4, and 5 on his behalf.…more
$0.9959-0.39%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14After-hours26.10.15 05:05#●●●#●●●
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Lisata Therapeutics has appointed biopharma financial veteran Jeff Farrow to its Board of Directors. The company aims to leverage his extensive experience in clinical development and commercialization to support its ongoing programs.…more
$0.9959-0.39%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.6Pre-market26.10.06 21:52
●●●●●●●● ●●●●● ●●●●●●
Lisata Therapeutics has been granted a US patent for methods of treating pancreatic cancer and other solid tumors. While this secures intellectual property for their drug development, further clinical validation is required to demonstrate commercial viability.…more
$0.9959-0.39%vs prev closeShareBenzinga - 10.5Pre-market26.10.05 21:00
●●●●●●●● ●●●●● ●●●●●●
Lisata Therapeutics' subsidiary, Marea Therapeutics, has initiated patient dosing in its Phase 2 clinical trial for the acromegaly treatment candidate MAR002. The drug aims to improve treatment convenience compared to current standards, though it remains in the early stages of clinical development.…more
$0.9959-0.39%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report